Drug Profile
Anti CCR2 monoclonal antibody
Latest Information Update: 20 Jul 2006
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coronary artery restenosis; Vascular restenosis
Most Recent Events
- 20 Jul 2006 Discontinued - Preclinical for Coronary artery restenosis in USA (unspecified route)
- 20 Jul 2006 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)
- 21 Nov 2001 Preclinical development for Coronary artery restenosis in USA (Unknown route)